Skip to content
This website uses cookies to help us understand the way visitors use our website. We can't identify you with them and we don't share the data with anyone else. If you click Reject we will set a single cookie to remember your preference. Find out more in our privacy policy.

UCLPartners supports applications for latest round of Pathway Transformation Funding

8 June 2021
We are supporting applications for Pathway Transformation Funding for rapid uptake products.

We are supporting our partner NHS organisations on the current round of applications for Pathway Transformation Funding for rapid uptake products. 

The Pathway Transformation Fund helps NHS organisations integrate the rapid uptake products (NICE-approved proven innovations targeting clinical priorities set out in the NHS Long Term Plan) into everyday practice, with support from Academic Health Science Networks (AHSNs). In the previous application cycle, 51 projects worth almost £2.8 million were supported nationally. 

Applications for Tamoxifen-related products – prescribed for the prevention of breast cancer – will be accepted from 7 June to 9 July 2021.

Through our role as one of 15 AHSNs across England, we are supporting organisations with the application process. We have previously supported successful applications for Pathway Transformation Funding for Lipids Management and FeNO.

More information and contact

For more information and help with your application please contact gareth.cairns@uclpartners.com

For the latest updates on the Pathway Transformation Fund please visit: https://www.england.nhs.uk/aac/what-we-do/how-can-the-aac-help-me/pathway-transformation-fund/